Pfizer Combo Drug Gets New Exclusivity After Ferring Win
The U.S. Food and Drug Administration will award Pfizer Inc.'s combination menopause drug the same five-year exclusivity that a Washington, D.C., federal judge previously granted Ferring Pharmaceuticals Inc.'s combination colonoscopy drug,...To view the full article, register now.
Already a subscriber? Click here to view full article